Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy. METHODS: We randomly assigned patients, in a 2:1 ratio, to receive durvalumab (at a dose of 10 mg per kilogram of body weight intravenously) or placebo every 2 weeks for up to 12 months. The study drug was administered 1 to 42 days after the patients had received chemoradiotherapy. The coprimary end points were progression-free survival (as assessed by means of blinded independent central review) and overall survival (unplanned for the interim analysis). Secondary end points included 12-month and 18-month progression-free survival rates, the objective response rate, the duration of response, the time to death or distant metastasis, and safety. RESULTS: Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo). The median progression-free survival from randomization was 16.8 months (95% confidence interval [CI], 13.0 to 18.1) with durvalumab versus 5.6 months (95% CI, 4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% CI, 0.42 to 0.65; P<0.001); the 12-month progression-free survival rate was 55.9% versus 35.3%, and the 18-month progression-free survival rate was 44.2% versus 27.0%. The response rate was higher with durvalumab than with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 months). The median time to death or distant metastasis was longer with durvalumab than with placebo (23.2 months vs. 14.6 months; P<0.001). Grade 3 or 4 adverse events occurred in 29.9% of the patients who received durvalumab and 26.1% of those who received placebo; the most common adverse event of grade 3 or 4 was pneumonia (4.4% and 3.8%, respectively). A total of 15.4% of patients in the durvalumab group and 9.8% of those in the placebo group discontinued the study drug because of adverse events. CONCLUSIONS: Progression-free survival was significantly longer with durvalumab than with placebo. The secondary end points also favored durvalumab, and safety was similar between the groups. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical benefi t with maintenance ICT in specifi c settings was demonstrated in patients with nonsmall cell lung cancer (NSCLC; ref.50 ), extensive-stage small cell lung cancer ( 51,52 ), and bladder cancer ( 53 ), leading to FDA approvals in these tumor types.”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [50]
In the citing paper
“By contrast, ICB has shown promise in the adjuvant setting in patients with melanoma or NSCLC57–59”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Bradley, J. D., Paulus, R., Komaki, R., Masters, G., Blumenschein, G., Schild, S., Bogart, J., Hu, C., Forster, K., Magliocco, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71207-0 · Cited by 2,015
Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H. C., Paulus, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2543 · Cited by 1,878
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Dovedi, S. J., Adlard, A. L., Lipowska-Bhalla, G., McKenna, C., Jones, S., Cheadle, E. J., Stratford, I. J., Poon, E., Morrow, M., Stewart, R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1258 · Cited by 1,313
Kelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., Lau, D. H. M., Crowley, J. J., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4824 · Cited by 573
Butts, C., Socinski, M. A., Mitchell, P. L., Thatcher, N., Havel, L., Krzakowski, M., Nawrocki, S., Ciuleanu, T.-E., Bosquée, L., Trigo, J. M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70510-2 · Cited by 538
Hanna, N., Neubauer, M., Yiannoutsos, C., McGarry, R., Arseneau, J., Ansari, R., Reynolds, C., Govindan, R., Melnyk, A., Fisher, W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7840 · Cited by 491
Vansteenkiste, J., De Ruysscher, D., Eberhardt, W. E. E., Lim, E., Senan, S., Felip, E., & Peters, S. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt241 · Cited by 490
Research works printed but not linked: 1
- Ettinger S, Wood DE, Aisner DL, et al. Non-small cell lung cancer, Version 5.2017. J Natl Compr Canc Netw 2017; 15: 504-35.
Cited by
Items 101–200 of 1,008
Time to abandon single-site irradiation for inducing abscopal effects
Brooks, E. D., & Chang, J. Y. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0119-7 · Cited by 313
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
Holder, A. M., Dedeilia, A., Sierra-Davidson, K., Cohen, S., Liu, D., Parikh, A., & Boland, G. M. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00705-7 · Cited by 298
Demaria, S., Guha, C., Schoenfeld, J., Morris, Z., Monjazeb, A., Sikora, A., Crittenden, M., Shiao, S., Khleif, S., Gupta, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002038 · Cited by 301
Bott, M. J., Yang, S. C., Park, B. J., Adusumilli, P. S., Rusch, V. W., Isbell, J. M., Downey, R. J., Brahmer, J. R., Battafarano, R., Bush, E., et al. (2019) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2018.11.124 · Cited by 305
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
Ciardiello, D., Vitiello, P. P., Cardone, C., Martini, G., Troiani, T., Martinelli, E., & Ciardiello, F. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.04.003 · Cited by 304
Kostine, M., Finckh, A., Bingham, C. O., Visser, K., Leipe, J., Schulze-Koops, H., Choy, E. H., Benesova, K., Radstake, T. R. D. J., Cope, A. P., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217139 · Cited by 290
Safety of combining radiotherapy with immune-checkpoint inhibition
Hwang, W. L., Pike, L. R. G., Royce, T. J., Mahal, B. A., & Loeffler, J. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0046-7 · Cited by 295
Mamlouk, O., Selamet, U., Machado, S., Abdelrahim, M., Glass, W. F., Tchakarov, A., Gaber, L., Lahoti, A., Workeneh, B., Chen, S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0478-8 · Cited by 296
Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline
Daly, M. E., Singh, N., Ismaila, N., Antonoff, M. B., Arenberg, D. A., Bradley, J., David, E., Detterbeck, F., Früh, M., Gubens, M. A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02528 · Cited by 283
Zerdes, I., Matikas, A., Bergh, J., Rassidakis, G. Z., & Foukakis, T. (2018) · Oncogene · doi:10.1038/s41388-018-0303-3 · Cited by 292
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Xu-Monette, Z. Y., Zhang, M., Li, J., & Young, K. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01597 · Cited by 288
Hack, S. P., Zhu, A. X., & Wang, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.598877 · Cited by 286
Du, B., Qin, J., Lin, B., Zhang, J., Li, D., & Liu, M. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.019 · Cited by 254
The Integration of Radiotherapy with Immunotherapy for the Treatment of Non–Small Cell Lung Cancer
Ko, E. C., Raben, D., & Formenti, S. C. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3620 · Cited by 278
Jabbour, S. K., Lee, K. H., Frost, N., Breder, V., Kowalski, D. M., Pollock, T., Levchenko, E., Reguart, N., Martinez-Marti, A., Houghton, B., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2301 · Cited by 270
Self-citationNon-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
Mithoowani, H., & Febbraro, M. (2022) · Current Oncology · doi:10.3390/curroncol29030150 · Cited by 259
Tinganelli, W., & Durante, M. (2020) · Cancers · doi:10.3390/cancers12103022 · Cited by 267
Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer
Nagasaka, M., & Gadgeel, S. M. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1409624 · Cited by 270
Loibl, S., Schneeweiss, A., Huober, J., Braun, M., Rey, J., Blohmer, J.-U., Furlanetto, J., Zahm, D.-M., Hanusch, C., Thomalla, J., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.1940 · Cited by 262
Yu, Y., Zeng, D., Ou, Q., Liu, S., Li, A., Chen, Y., Lin, D., Gao, Q., Zhou, H., Liao, W., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.6879 · Cited by 261
Zhou, Q., Chen, M., Jiang, O., Pan, Y., Hu, D., Lin, Q., Wu, G., Cui, J., Chang, J., Cheng, Y., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00630-6 · Cited by 244
Tu, X., Qin, B., Zhang, Y., Zhang, C., Kahila, M., Nowsheen, S., Yin, P., Yuan, J., Pei, H., Li, H., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.04.005 · Cited by 263
Chan, A. T. C., Hui, E. P., Ngan, R. K. C., Tung, S. Y., Cheng, A. C. K., Ng, W. T., Lee, V. H. F., Ma, B. B. Y., Cheng, H. C., Wong, F. C. S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.7847 · Cited by 252
Girard, N., Bar, J., Garrido, P., Garassino, M. C., McDonald, F., Mornex, F., Filippi, A. R., Smit, H. J. M., Peters, S., Field, J. K., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.10.003 · Cited by 247
Brahmer, J. R., Govindan, R., Anders, R. A., Antonia, S. J., Sagorsky, S., Davies, M. J., Dubinett, S. M., Ferris, A., Gandhi, L., Garon, E. B., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0382-2 · Cited by 253
Self-citationFournel, L., Wu, Z., Stadler, N., Damotte, D., Lococo, F., Boulle, G., Ségal-Bendirdjian, E., Bobbio, A., Icard, P., Trédaniel, J., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.08.005 · Cited by 249
Zhao, Y., Guo, S., Deng, J., Shen, J., Du, F., Wu, X., Chen, Y., Li, M., Chen, M., Li, X., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.70958 · Cited by 246
YTHDF2 inhibition potentiates radiotherapy antitumor efficacy
Wang, L., Dou, X., Chen, S., Yu, X., Huang, X., Zhang, L., Chen, Y., Wang, J., Yang, K., Bugno, J., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.04.019 · Cited by 246
“12,13 These trials utilized checkpoint blockade after chemo/ radiotherapy to inhibit microscopic metastatic disease, however a consistent meaningful interaction between checkpoint immunotherapy and radiotherapy in humans has yet to be established.”
Self-citationKaplon, H., & Reichert, J. M. (2018) · mAbs · doi:10.1080/19420862.2018.1415671 · Cited by 244
Couey, M. A., Bell, R. B., Patel, A. A., Romba, M. C., Crittenden, M. R., Curti, B. D., Urba, W. J., & Leidner, R. S. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0645-6 · Cited by 243
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Peyraud, F., & Italiano, A. (2020) · Cancers · doi:10.3390/cancers12061502 · Cited by 242
Development of PARP and immune-checkpoint inhibitor combinations
Stewart, R. A., Pilié, P. G., & Yap, T. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-2652 · Cited by 239
Lung Cancer in People’s Republic of China
Gao, S., Li, N., Wang, S., Zhang, F., Wei, W., Li, N., Bi, N., Wang, Z., & He, J. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.04.028 · Cited by 237
Developing neoantigen-targeted T cell–based treatments for solid tumors
Yamamoto, T. N., Kishton, R. J., & Restifo, N. P. (2019) · Nature Medicine · doi:10.1038/s41591-019-0596-y · Cited by 238
Waterhouse, D. M., Garon, E. B., Chandler, J., McCleod, M., Hussein, M., Jotte, R., Horn, L., Daniel, D. B., Keogh, G., Creelan, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00131 · Cited by 235
Self-citationRodak, O., Peris-Díaz, M. D., Olbromski, M., Podhorska-Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 233
Monk, B. J., Toita, T., Wu, X., Vázquez Limón, J. C., Tarnawski, R., Mandai, M., Shapira-Frommer, R., Mahantshetty, U., del Pilar Estevez-Diz, M., Zhou, Q., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00479-5 · Cited by 229
Clinical development of targeted and immune based anti-cancer therapies
Seebacher, N. A., Stacy, A. E., Porter, G. M., & Merlot, A. M. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1094-2 · Cited by 231
Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
Sosa Iglesias, V., Giuranno, L., Dubois, L. J., Theys, J., & Vooijs, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00267 · Cited by 229
“8% 18-month response) in stage III unresectable NSCLC pre-treated with platinum-based chemotherapy (23, 24).”
BackgroundCardiovascular Toxicities of Immune Checkpoint Inhibitors
Ball, S., Ghosh, R. K., Wongsaengsak, S., Bandyopadhyay, D., Ghosh, G. C., Aronow, W. S., Fonarow, G. C., Lenihan, D. J., & Bhatt, D. L. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.079 · Cited by 222
Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
Yan, Y., Kumar, A. B., Finnes, H., Markovic, S. N., Park, S., Dronca, R. S., & Dong, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01739 · Cited by 223
Paz-Ares, L., Spira, A., Raben, D., Planchard, D., Cho, B. C., Özgüroğlu, M., Daniel, D., Villegas, A., Vicente, D., Hui, R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.287 · Cited by 224
Self-citationOptimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
Grapin, M., Richard, C., Limagne, E., Boidot, R., Morgand, V., Bertaut, A., Derangere, V., Laurent, P.-A., Thibaudin, M., Fumet, J. D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0634-9 · Cited by 217
Higgs, B. W., Morehouse, C. A., Streicher, K., Brohawn, P. Z., Pilataxi, F., Gupta, A., & Ranade, K. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3451 · Cited by 220
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer
Petroni, G., Cantley, L. C., Santambrogio, L., Formenti, S. C., & Galluzzi, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00579-w · Cited by 213
Squamous cell lung cancer: Current landscape and future therapeutic options
Lau, S. C. M., Pan, Y., Velcheti, V., & Wong, K. K. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.09.018 · Cited by 207
Lamano, J. B., Lamano, J. B., Li, Y. D., DiDomenico, J. D., Choy, W., Veliceasa, D., Oyon, D. E., Fakurnejad, S., Ampie, L., Kesavabhotla, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2402 · Cited by 209
Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer
Judd, J., Abdel Karim, N., Khan, H., Naqash, A. R., Baca, Y., Xiu, J., VanderWalde, A. M., Mamdani, H., Raez, L. E., Nagasaka, M., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0201 · Cited by 194
Update 2025: Management of Non‑Small-Cell Lung Cancer
Jeon, H., Wang, S., Song, J., Gill, H., & Cheng, H. (2025) · Lung · doi:10.1007/s00408-025-00801-x · Cited by 190
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Passaro, A., Leighl, N., Blackhall, F., Popat, S., Kerr, K., Ahn, M. J., Arcila, M. E., Arrieta, O., Planchard, D., de Marinis, F., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.003 · Cited by 200
Self-citationHsu, P.-C., Jablons, D. M., Yang, C.-T., & You, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153821 · Cited by 205
Cho, J. Y., Kim, J., Lee, J. S., Kim, Y. J., Kim, S. H., Lee, Y. J., Cho, Y.-J., Yoon, H. I., Lee, J. H., Lee, C.-T., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.09.015 · Cited by 208
Self-citationLooi, C.-K., Chung, F. F.-L., Leong, C.-O., Wong, S.-F., Rosli, R., & Mai, C.-W. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1153-8 · Cited by 202
Liu, X., Zhang, Y., Yang, K.-Y., Zhang, N., Jin, F., Zou, G.-R., Zhu, X.-D., Xie, F.-Y., Liang, X.-Y., Li, W.-F., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00594-4 · Cited by 196
Kim, K. H., Cho, J., Ku, B. M., Koh, J., Sun, J.-M., Lee, S.-H., Ahn, J. S., Cheon, J., Min, Y. J., Park, S.-H., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1449 · Cited by 205
Pellini, B., & Chaudhuri, A. A. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01929 · Cited by 190
Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis
Jiang, S., Liu, Y., Zheng, H., Zhang, L., Zhao, H., Sang, X., Xu, Y., & Lu, X. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000492 · Cited by 189
Lan, Y., Moustafa, M., Knoll, M., Xu, C., Furkel, J., Lazorchak, A., Yeung, T.-L., Hasheminasab, S.-M., Jenkins, M. H., Meister, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.008 · Cited by 201
Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
Hofman, P., Heeke, S., Alix-Panabières, C., & Pantel, K. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz196 · Cited by 200
Pérez-Ruiz, E., Melero, I., Kopecka, J., Sarmento-Ribeiro, A. B., García-Aranda, M., & De Las Rivas, J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100718 · Cited by 196
Sui, H., Ma, N., Wang, Y., Li, H., Liu, X., Su, Y., & Yang, J. (2018) · Journal of Immunology Research · doi:10.1155/2018/6984948 · Cited by 199
Yang, J., & Hu, L. (2019) · Medicinal Research Reviews · doi:10.1002/med.21530 · Cited by 190
Metabolism in tumor microenvironment: Implications for cancer immunotherapy
Shi, R., Tang, Y., & Miao, H. (2020) · MedComm · doi:10.1002/mco2.6 · Cited by 198
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Self-citationKRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
Adderley, H., Blackhall, F. H., & Lindsay, C. R. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.049 · Cited by 195
Immune checkpoint inhibitors: a promising anticancer therapy
Singh, S., Hassan, D., Aldawsari, H. M., Molugulu, N., Shukla, R., & Kesharwani, P. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.11.003 · Cited by 189
Ladbury, C. J., Rusthoven, C. G., Camidge, D. R., Kavanagh, B. D., & Nath, S. K. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.05.064 · Cited by 186
Gong, J., Le, T. Q., Massarelli, E., Hendifar, A. E., & Tuli, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0361-7 · Cited by 191
Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer
Atchley, W. T., Alvarez, C., Saxena-Beem, S., Schwartz, T. A., Ishizawar, R. C., Patel, K. P., & Rivera, M. P. (2021) · Chest · doi:10.1016/j.chest.2021.02.032 · Cited by 186
Komiya, T., & Huang, C. H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00423 · Cited by 186
Hui, R., Özgüroğlu, M., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30519-4 · Cited by 187
Self-citationSuresh, K., Psoter, K. J., Voong, K. R., Shankar, B., Forde, P. M., Ettinger, D. S., Marrone, K. A., Kelly, R. J., Hann, C. L., Levy, B., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.016 · Cited by 186
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma
Kim, C. G., Kim, C., Yoon, S. E., Kim, K. H., Choi, S. J., Kang, B., Kim, H. R., Park, S.-H., Shin, E.-C., Kim, Y.-Y., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.010 · Cited by 185
Self-citationPike, L. R. G., Bang, A., Mahal, B. A., Taylor, A., Krishnan, M., Spektor, A., Cagney, D. N., Aizer, A. A., Alexander, B. M., Rahma, O., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.09.010 · Cited by 183
Radiotherapy-Related Lymphopenia Affects Overall Survival in Patients With Lung Cancer
Abravan, A., Faivre-Finn, C., Kennedy, J., McWilliam, A., & van Herk, M. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.06.008 · Cited by 183
Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer
Gaynor, N., Crown, J., & Collins, D. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.016 · Cited by 182
Peng, X.-X., Yu, R., Wu, X., Wu, S.-Y., Pi, C., Chen, Z.-H., Zhang, X.-C., Gao, C.-Y., Shao, Y. W., Liu, L., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000376 · Cited by 182
The Reciprocity between Radiotherapy and Cancer Immunotherapy
Wang, Y., Liu, Z.-G., Yuan, H., Deng, W., Li, J., Huang, Y., Kim, B. Y. S., Story, M. D., & Jiang, W. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2581 · Cited by 181
Self-citationBando, H., Tsukada, Y., Inamori, K., Togashi, Y., Koyama, S., Kotani, D., Fukuoka, S., Yuki, S., Komatsu, Y., Homma, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3213 · Cited by 170
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
Onoi, K., Chihara, Y., Uchino, J., Shimamoto, T., Morimoto, Y., Iwasaku, M., Kaneko, Y., Yamada, T., & Takayama, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051362 · Cited by 183
Ultra-high dose rate effect on circulating immune cells: A potential mechanism for FLASH effect?
Jin, J.-Y., Gu, A., Wang, W., Oleinick, N. L., Machtay, M., & (Spring) Kong, F.-M. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.04.054 · Cited by 178
Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features
Ellis, S. R., Vierra, A. T., Millsop, J. W., Lacouture, M. E., & Kiuru, M. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.04.105 · Cited by 175
Chen, Y., Gao, M., Huang, Z., Yu, J., & Meng, X. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00940-z · Cited by 178
“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
Torlakovic, E., Lim, H. J., Adam, J., Barnes, P., Bigras, G., Chan, A. W. H., Cheung, C. C., Chung, J.-H., Couture, C., Fiset, P. O., et al. (2020) · Modern Pathology · doi:10.1038/s41379-019-0327-4 · Cited by 178
Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival
Casal-Mouriño, A., Ruano-Ravina, A., Lorenzo-González, M., Rodríguez-Martínez, Á., Giraldo-Osorio, A., Varela-Lema, L., Pereiro-Brea, T., Barros-Dios, J. M., Valdés-Cuadrado, L., & Pérez-Ríos, M. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.03.40 · Cited by 177
Predicting tumour radiosensitivity to deliver precision radiotherapy
Price, J. M., Prabhakaran, A., & West, C. M. L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00709-y · Cited by 167
The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances
Janopaul-Naylor, J. R., Shen, Y., Qian, D. C., & Buchwald, Z. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011061 · Cited by 169
Lee, J. B., Kim, H. R., & Ha, S.-J. (2022) · Immune Network · doi:10.4110/in.2022.22.e2 · Cited by 174
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Sato, H., Okonogi, N., & Nakano, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01666-1 · Cited by 173
Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy
Shevtsov, M., Sato, H., Multhoff, G., & Shibata, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00156 · Cited by 173
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
Majem, M., Juan, O., Insa, A., Reguart, N., Trigo, J. M., Carcereny, E., García-Campelo, R., García, Y., Guirado, M., & Provencio, M. (2019) · Clinical and Translational Oncology · doi:10.1007/s12094-018-1978-1 · Cited by 173
Wei, J., Montalvo-Ortiz, W., Yu, L., Krasco, A., Ebstein, S., Cortez, C., Lowy, I., Murphy, A. J., Sleeman, M. A., & Skokos, D. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg0117 · Cited by 169
Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association
Beavers, C. J., Rodgers, J. E., Bagnola, A. J., Beckie, T. M., Campia, U., Di Palo, K. E., Okwuosa, T. M., Przespolewski, E. R., Dent, S., & on behalf of the American Heart Association Clinical Pharmacology Committee and Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine; and the Council on Peripheral Vascular Disease (2022) · Circulation · doi:10.1161/cir.0000000000001056 · Cited by 150
Durm, G. A., Jabbour, S. K., Althouse, S. K., Liu, Z., Sadiq, A. A., Zon, R. T., Jalal, S. I., Kloecker, G. H., Williamson, M. J., Reckamp, K. L., et al. (2020) · Cancer · doi:10.1002/cncr.33083 · Cited by 164
Lin, Z., Cai, M., Zhang, P., Li, G., Liu, T., Li, X., Cai, K., Nie, X., Wang, J., Liu, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003554 · Cited by 166
Pinto, J. A., Vallejos, C. S., Raez, L. E., Mas, L. A., Ruiz, R., Torres-Roman, J. S., Morante, Z., Araujo, J. M., Gómez, H. L., Aguilar, A., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000344 · Cited by 164
Zer, A., Ahn, M., Barlési, F., Bubendorf, L., Ruysscher, D. D., Garrido, P., Gautschi, O. P., Hendriks, L. E. L., Janne, P. A., Kerr, K. M., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.08.003 · Cited by 227
Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
Mushtaq, M. U., Papadas, A., Pagenkopf, A., Flietner, E., Morrow, Z., Chaudhary, S. G., & Asimakopoulos, F. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0376-0 · Cited by 165
Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
Abu-Sbeih, H., Tang, T., Lu, Y., Thirumurthi, S., Altan, M., Jazaeri, A. A., Dadu, R., Coronel, E., & Wang, Y. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0502-7 · Cited by 162
Lv, J., Chen, Y., Zhou, G., Qi, Z., Tan, K. R. L., Wang, H., Lin, L., Chen, F., Zhang, L., Huang, X., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11853-y · Cited by 161
Metadata
- Authors
- Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., Cho, B. C., Bourhaba, M., Quantin, X., Tokito, T., Mekhail, T., Planchard, D., Kim, Y.-C., Karapetis, C. S., Hiret, S., Ostoros, G., Kubota, K., Gray, J. E., Paz-Ares, L., de Castro Carpeño, J., Wadsworth, C., Melillo, G., Jiang, H., Huang, Y., Dennis, P. A., & Özgüroğlu, M.
- Affiliations
- Institut Gustave Roussy (FR)
- From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and Florida Hospital Cancer Institute, Orlando (T.M.) — all in Florida; Tennessee Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville — both in Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de Cáncer, Universidad Complutense and...
- ORCID
- Antonia, Scott J.
- Villegas, Augusto
- Daniel, Davey
- Vicente, David
- Murakami, Shuji
- Hui, Rina
- Yokoi, Takashi
- Chiappori, Alberto
- Lee, Ki H.
- Cho, Byoung C.
- Quantin, Xavier
- Tokito, Takaaki
- Planchard, David
- Kim, Young-Chul
- Karapetis, Christos S.
- Hiret, Sandrine
- Ostoros, Gyula
- Kubota, Kaoru
- Gray, Jhanelle E.
- Paz-Ares, Luis
- Jiang, Haiyi
- Huang, Yifan
- Özgüroğlu, Mustafa
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-16
- Volume
- 377
- Issue
- 20
- Pages
- 1919-1929
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2753065806
- Cited by
- 4,593
- References
- 22
- Citations by year
- 2026: 380 · 2025: 463 · 2024: 496 · 2023: 548 · 2022: 555 · 2021: 625 · 2020: 563 · 2019: 463 · 2018: 451 · 2017: 46
- FWCI
- 183.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- HAL (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Lirias (submittedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Cancer Research UK (20465)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- durvalumab, non-small cell lung cancer, stage III NSCLC, consolidation therapy, chemoradiotherapy, PD-L1 inhibitors, progression-free survival, overall survival, objective response rate, locally advanced unresectable lung cancer, immune checkpoint inhibitors, platinum-based chemotherapy, radiotherapy, distant metastasis, treatment safety, adverse events
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Disease-Free Survival, Kaplan-Meier Estimate, Intention to Treat Analysis, Chemoradiotherapy, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.